Moreover, BsAb not only offers an effective linkage between therapeutics (e.g., immune effector cells, radionuclides) and targets (e.g., tumor cells) but also simultaneously blocks two different oncogenic mediators such as anti-epidermal growth factor receptor (EGFR) × anti-HER2 and anti- EGFR × anti-c-MET [12, 13]. Here, EGFR is linked to neoplasm.